Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial.
Randomized controlled trial published in Archives of disease in childhood (2006)
Abstract
OBJECTIVES: To determine whether the tissue plasminogen activator, alteplase, is more effective than heparin in preventing blood clots developing in children's haemodialysis central lines between dialysis sessions. DESIGN: A prospective double-blind, within-patient multiperiod cross-over controlled trial of instilling a "lock" of either heparin 5000 U/ml or alteplase 1 mg/ml into the central lines of two children haemodialysed twice weekly, and seven dialysed thrice weekly, over 10 weeks. SETTING: A UK paediatric nephrology unit. MAIN OUTCOME MEASURES: Weight of blood clot aspirated from the line at the start of the next dialysis session. RESULTS: The odds of a clot forming was 2.4 times greater with heparin than alteplase (95% CI 1.4 to 4.0; p = 0.001), and when present they were 1.9 times heavier (31 vs 15 mg; 95% CI 1.5 to 2.4; p<0.0005). There was no effect of inter-dialytic interval. One child required an alteplase infusion to clear a blocked line following a heparin lock. We subsequently changed our routine locks from heparin to alteplase. Comparing the year before and after that change, the incidence of blocked lines requiring an alteplase or urokinase infusion fell from 2.7 to 1.2 per child (p<0.03), and the need for surgical replacements from 0.7 to nil (p<0.02). CONCLUSION: Alteplase is significantly more effective than heparin in preventing clot formation in central haemodialysis lines. This reduces morbidity and improves preservation of central venous access. It is more expensive, though relatively economic if packaged into syringes and stored frozen until needed, but reduces the costs of unblocking or replacing clotted lines.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
To determine whether the tissue plasminogen activator, alteplase, is more effective than heparin in preventing blood clots developing in children's haemodialysis central lines between dialysis sessions. A prospective double-blind, within-patient multiperiod cross-over controlled trial of instilling...
Warum dies für die Hirudotherapie relevant ist
Diese prospektive, doppelblinde, innerhalb des Patienten cross-over-kontrollierte Studie mit mehreren Perioden verglich Alteplase mit Heparin als Verschlusslösungen zur Verhinderung von Blutgerinnseln in pädiatrischen zentralvenösen Hämodialysezugängen bei neun Kindern über einen Zeitraum von 10 Wochen. Das Abstract berichtet, dass Alteplase signifikant wirksamer war als Heparin, mit 2,4-fach niedrigerer Odds für Gerinnselbildung und leichteren Gerinnseln, sofern vorhanden. Die Studie untersucht das pharmazeutische Antikoagulationsmanagement von Dialysekathetern. Das Abstract enthält keinerlei Erwähnung von Blutegeln, Hirudotherapie oder von Blutegel-abgeleiteten Verbindungen, sodass seine Relevanz für den ASH-Bereich ausschließlich indirekt ist und lediglich einen kontextuellen Hintergrund zur Anwendung von Antikoagulanzien im klinischen Setting darstellt.
Zitation
Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial.
Gittins et al. · Archives of disease in childhood, 2006
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026